Table 1.
Baseline characteristics of participants
| Rosuvastatin users (n = 126) | Non‐users (n = 119*) | |
|---|---|---|
| General | ||
| Age (years) | 56.8 (19–82) | 58.4 (21–80) |
| Male | 68 (54) | 82 (69) |
| Body mass index (kg m−2) | 27.4 (19.2–43.5) | 27.7 (17.2–43.3) |
| Aspirin use | 5 (4) | 5 (4) |
| Venous thrombosis characteristics | ||
| Type of venous thromboembolism | ||
| Deep vein thrombosis | 72 (57) | 64 (54) |
| Pulmonary embolism | 54 (43) | 55 (46) |
| Unprovoked | 57 (45) | 62 (52) |
| Provoked, by | 69 (55) | 57 (48) |
| Surgery/trauma/immobilization | 32 (25) | 30 (25) |
| Travel >4 h | 22 (18) | 14 (12) |
| Estrogen use (% in women) | 24 (41) | 14 (38) |
| Pregnancy/puerperium (% in women) | 0 (0) | 2 (5) |
| Malignancy | 2 (2) | 8 (7) |
| Recurrent venous thrombosis | 10 (8) | 8 (7) |
| Cardiovascular risk factors | ||
| Cardiovascular risk | 89 (71) | 94 (78) |
| Current smoking | 18 (14) | 16 (13) |
| Hypertension | 24 (19) | 20 (17) |
| Diabetes | 3 (2) | 0 (0) |
| Overweight† | 54 (43) | 51 (43) |
| Obesity‡ | 29 (23) | 34 (28) |
Continuous variables denoted as mean (range), categorical variables as n (%). *Technical issues in two non‐users. †Overweight was defined as body mass index (BMI) between 25 and 30 kg m−2. ‡Obesity was defined as BMI above 30 kg m−2.